1. DR Hill et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.

2. Adult immunization. Treat Guidel Med Lett 2011; 9:75.

3. General recommendations on immunizations – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(2):1.

4. RM Klevens et al. The evolving epidemiology of hepatitis A in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med 2010; 170:1811.

5. S Iwarson et al. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004; 11:120.

6. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56:1080.

7. R Steffen. Influenza in travelers: epidemiology, risk, prevention, and control issues. Curr Infect Dis Rep 2010; 12:181.

8. Influenza vaccine for 2011-2012. Med Lett Drugs Ther 2011; 53:81.

9. Centers for Disease Control and Prevention (CDC). Use of northern hemisphere influenza vaccines by travelers to the southern hemisphere. MMWR Morb Mortal Weekly Rep 2009; 58:312.

10. SL Hills et al. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010; 82:930.

11. E Mirzaian et al. Mosquito-borne illness in travelers: a review of risk and prevention. Pharmacotherapy 2010; 30:1031.

12. A new Japanese encephalitis vaccine (Ixiaro). Med Lett Drugs Ther 2009; 51:66.

13. SB Halstead and SJ Thomas. Japanese encephalitis: new options for active immunization. Clin Infect Dis 2010; 50:1155.

14. CDC. Update on Japanese encephalitis vaccine for children: United States, May 2011. MMWR Morb Mortal Wkly Rep 2011; 60:644.

15. A Kaltenböck et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834.

16. PJ Edelson and JA Anderson. Reported cases of measles in international air travelers to the United States, August 2005-March 2008. J Travel Med 2011; 18:178.

17. CDC. Measles imported by returning US travelers aged 6-23 months, 2001-2011. MMWR Morb Mortal Wkly Rep 2011; 60:397.

18. R Steffen. The risk of meningococcal disease in travels and current recommendations for prevention. J Travel Med 2010; 17 Suppl: 9.

19. A new conjugate meningococcal vaccine (Menveo). Med Lett Drugs Ther 2010; 52:59.

20. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.

21. Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses—worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep 2011; 60:846.

22. C Malerczyk et al. Imported human rabies cases in Europe, the United States, and Japan, 1990-2010. J Travel Med 2011; 18:402.

23. CE Rupprecht and RV Gibbons. Clinical practice. Prophylaxis against rabies. N Engl J Med 2004; 351:2626.

24. CE Rupprecht et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2010; 59(RR-2):1.

25. Adacel and Boostrix: Tdap vaccines for adolescents and adults. Med Lett Drugs Ther 2006; 48:5.

26. ACIP Provisional Tdap Recommendations. March 21, 2012. Available at www.cdc.gov/vaccines/recs/provisional/Tdap-feb2012.htm. Accessed May 16, 2012.

27. MF Lynch et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859.

28. JA Whitaker et al. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009; 16:46.

29. JE Staples et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-7):1.

30. N Bhadelia et al. The HIV-positive traveler. Am J Med 2007; 120:574.

31. AW McMahon et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007; 25:1727.

32. RE Thomas et al. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 2012; 86:359.

33. MF Farez and J Correale. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011; 68:1267.

34. S Kuhn et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 2011; 183:E243.

35. RC Charles and ET Ryan. Cholera in the 21st century. Curr Opin Infect Dis 2011; 24:472.

36. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:117.

37. A Banzhoff et al. Protection against tick-borne encephalitis (TBE) for people living in and traveling to TBE-endemic areas. Travel Med Infect Dis 2008; 6:331.

38. U Kunze. Is there a need for a travel vaccination against tick-borne encephalitis? Travel Med Infect Dis 2008; 6:380.

39. N Apelt et al. The prevalence of Norovirus in returning international travelers with diarrhea. BMC Infect Dis 2010; 10:131.

40. HL DuPont et al. Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med 2009; 16:161.

41. D Jain et al. Campylobacter species and drug resistance in a north Indian rural community. Trans R Soc Trop Med Hyg 2005; 99:207.

42. DR Tribble et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338.

43. KS Hong and JS Kim. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol 2011; 4:227.

44. HL DuPont et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med 2009; 16:149.

45. HL DuPont et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805.

46. AW Armstrong et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. J Travel Med 2010; 17:392.

47. F Martinez-Sandoval et al. Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med 2010; 17:111.

48. DO Freedman. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.

49. PJ van Genderen et al. The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of Plasmodium falciparum malaria in non-immune travelers and expatriates [corrected]. J Travel Med 2007; 14:92.

50. E Schwartz et al. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 2003; 37:450.

51. A Färnert et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 2003; 326:628.

52. S Kuhn et al. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a nonimmune North American traveller to west Africa. Am J Trop Med Hyg 2005; 72:407.

53. CT Happi et al. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malaria J 2006; 5:82.

54. J Ling et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825.

55. J Soto et al. Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers. Am J Trop Med Hyg 2006; 75:430.

56. LH Chen et al. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.

57. P Schlagenhauf et al. Use of mefloquine in children – a review of dosage, pharmacokinetics and tolerability data. Malar J 2011; 10:292.

58. DR Hill et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.

59. P Schlagenhauf et al. Pregnancy and fetal outcomes after exposure to Mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54:e124. Epub 2012 Apr 10.

60. MH Irvine et al. Prophylactic use of antimalarials during pregnancy. Can Fam Physician 2011; 57:1279.

61. R McGready et al. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg 2001; 65:285.

62. Sunscreens: an update. Med Lett Drugs Ther 2008; 50:70.

63. A Badolo et al. Evaluation of the sensitivity of Aedes aegypti and Anopheles gambiae complex mosquitoes to two insect repellents: DEET and KBR 3023. Trop Med Int Health 2004; 9:330.

64. SP Frances et al. Laboratory and field evaluation of commercial repellent formulations against mosquitoes (diptera: culcidae) in Queensland, Australia. Aust J Entomol 2005; 44:431.

65. C Constantini et al. Field evaluation of the efficacy and persistence of insect repellents DEET, IR3535, and KBR 3023 against Anopheles gambiae complex and other Afrotropical vector mosquitoes. Trans R Soc Trop Med Hyg 2004; 98:644.

66. CP Simmons et al. Dengue. N Engl J Med 2012; 366:1423.

67. MG Guzman et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8(12 Suppl):S7.

68. A Pavli and HC Maltezou. Travel-acquired leptospirosis. J Travel Med 2008; 15:447.

69. SA Gallagher and PH Hackett. High-altitude illness. Emerg Med Clin North Am 2004; 22:329.

70. MJ McInnis et al. Evidence for a genetic basis for altitude illness: 2010 update. High Alt Med Biol 2010; 11:349.

71. AM Luks et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21:146.

72. BL Strom et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.

73. D Chandra et al. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 2009; 151:180.

74. SR Kahn et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.

75. M Clarke et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database Syst Rev 2006; (2):CD004002.

76. MR Cesarone et al. Venous thrombosis from air travel: the LONFLIT3 study–prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology 2002; 53:1.

77. RL Sack. Clinical practice. Jet lag. N Engl J Med 2010; 362:440.

78. J Waterhouse et al. Jet lag: trends and coping strategies. Lancet 2007; 369:1117.

79. AO Jamieson et al. Zolpidem reduces the sleep disturbance of jet lag. Sleep Med 2001; 2:423.

80. RP Rosenberg et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc 2010; 85:630.

81. JF Golding and MA Gresty. Motion sickness. Curr Opin Neurol 2005; 18:29.